Who are Course A2 + Vin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Flu/Cy/ATG or Cy/ATG, Cisplatin / Carboplatin，Gemcitabine，Cindilimab, Carboplatin, Etoposide, Ifosfamide, SOX Chemotherapy, CVP, chemotherapy plus p53.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/course-a2-vin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Course A2 + Vin — Competitive Intelligence Brief

Course A2 + Vin (Course A2 + Vin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy. Area: Oncology.

phase 3 Combination chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Course A2 + Vin (Course A2 + Vin) — Children's Cancer Group, China. Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Course A2 + Vin TARGET	Course A2 + Vin	Children's Cancer Group, China	phase 3	Combination chemotherapy
Flu/Cy/ATG or Cy/ATG	Flu/Cy/ATG or Cy/ATG	Peking University People's Hospital	marketed	Conditioning regimen (combination chemotherapy and immunosuppressive therapy)
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy class)

Children's Cancer Group, China · 1 drug in this class
EpicentRx, Inc. · 1 drug in this class
Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Course A2 + Vin — Competitive Intelligence Brief. https://druglandscape.com/ci/course-a2-vin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab